ForeSENTIA is an extensive portfolio of tumor profile panels that identify genetic alterations (changes) implicated in cancer. The ForeSENTIA panels test for alterations on genes that have important roles in cancer. Identifying these genetic alterations is beneficial for:
- providing an in-depth understanding of the molecular profile to the healthcare provider
- giving a better prognostic assessment
- allowing for more precise and effective medical recommendations
- improving clinical management and patient outcome
- guiding therapy options
ForeSENTIA has 2 panel categories – depending on your cancer type and its characteristics, your doctor will recommend the best panel for you.
COMPREHENSIVE TUMOR PROFILE PANELS
ForeSENTIA comprehensive tumor profile panels focus on a number of genetic changes found in specific cancer types.
-
BREAST / GYNECOLOGICAL
48
-
COLORECTAL
33
-
LUNG (NSCLC)
35
-
PROSTATE
30
-
MELANOMA
22
-
GLIOMA
22*
-
PAN-CANCER
77*
* 1p/19q codeletion is also tested in these panels and reported only in the context of glioma diagnosis.
BREAST/GYNECOLOGICAL TUMOR PROFILE PANEL
Description
The ForeSENTIA breast/ovarian tumor profile panel tests for numerous genetic alterations that are frequently found in gynecological tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.
Who is this test for?
Any patient diagnosed with breast or ovarian cancer can have tumor profile testing with the ForeSENTIA breast/ovarian panel to help identify the specific genetic alterations that are associated with their tumor.
Number Of Genes Tested
48
Sample: Unstained sections from tumor biopsy sample
Turnaround time: 2-3 Weeks
Genes Tested
The table below shows the genes tested by the ForeSENTIA beast/ovarian tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.
ForeSENTIA Breast/Ovarian Tumor Profile Panel
| Single Nucleotide Variants / Insertions and Deletions | Copy Number Alterations | Translocations |
|---|---|---|
| AKT1, ATM, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CHEK2, CTNNB1, DICER1, EGFR, ERBB2, ERBB3, ESR1, FBXW7, FOXA1, FOXL2, GATA3, KIT, KRAS, MAP3K1, MLH1, MSH2, MSH6, MRE11A, MTOR, NBN, NRAS, PALB2, PSM2, PIK3CA, PIK3CB, POLE, PTEN, RAD51C, RAD51D, RAF1, RET, RUNX1, SMAD4, TP53 | EGFR, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, KRAS, MET, PIK3CA, PTEN, TP53 | NTRK1, NTRK2, NTRK3 |
COLORECTAL TUMOR PROFILE PANEL
Description
The ForeSENTIA colorectal tumor profile panel tests for numerous genetic alterations that are frequently found in colorectal tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.
Who is this test for?
Any patient diagnosed with colorectal cancer can have tumor profile testing with the ForeSENTIA colorectal cancer panel to help identify the specific genetic alterations that are associated with their tumor.
Number Of Genes Tested
33
Sample: Unstained sections from tumor biopsy sample
Turnaround time: 2-3 Weeks
Genes Tested
The table below shows the genes tested by the ForeSENTIA colorectal tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.
ForeSENTIA Colorectal Tumor Profile Panel
| Single Nucleotide Variants / Insertions and Deletions | Copy Number Alterations | Translocations |
|---|---|---|
| AKT1, APC, ATM, BRAF, BRCA1, BRCA2, CTNNB1, EGFR, ERBB2, FBXW7, GNAS, KRAS, MLH1, MSH2, MSH6, MTOR, NRAS, NTRK1, PALB2, PIK3CA, PIK3CB, PMS2, POLE, PTEN, RAF1, SMAD4, TP53 | EGFR, ERBB2, FGFR1, FGFR2, FGFR3, KRAS, MET, TP53 | NTRK1, NTRK2, NTRK3 |
LUNG (NSCLC) TUMOR PROFILE PANEL
Description
The ForeSENTIA lung (NSCLC) tumor profile panel tests for numerous genetic alterations that are frequently found in lung (Non Small Cell Lung Cancers – NSCLC) tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.
Who is this test for?
Any patient diagnosed with lung (NSCLC) cancer can have tumor profile testing with the ForeSENTIA lung (NSCLC) panel to help identify the specific genetic alterations that are associated with their tumor.
Number Of Genes Tested
35
Sample: Unstained sections from tumor biopsy sample
Turnaround time: 2-3 Weeks
Genes Tested
The table below shows the genes tested by the ForeSENTIA lung (NSCLC) tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.
ForeSENTIA Lung (NSCLC) Tumor Profile Panel
| Single Nucleotide Variants / Insertions and Deletions | Copy Number Alterations | Translocations |
|---|---|---|
| AKT1, ALK, APC, ARAF, ATM,BRAF, BRCA2, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, FBXW7, JAK2, KEAP1, KRAS, MAP2K1, MET, NRAS, PIK3CA, POLE, PTEN, RAF1, SMAD4, STK11, TP53 | EGFR, ERBB2, FGFR1, FGFR2, FGFR3, MET, PIK3CA, PTEN, TP53 | ALK, FGFR3, NTRK1, NTRK2, NTRK3, RET, ROS1 |
MELANOMA TUMOR PROFILE PANEL
Description
The ForeSENTIA melanoma tumor profile panel tests for numerous genetic alterations that are frequently found in melanomas. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.
Who is this test for?
Any patient diagnosed with melanoma cancer can have tumor profile testing with the ForeSENTIA melanoma panel to help identify the specific genetic alterations that are associated with their tumor.
Number Of Genes Tested
22
Sample: Unstained sections from tumor biopsy sample
Turnaround time: 2-3 Weeks
Genes Tested
The table below shows the genes tested by the ForeSENTIA melanoma tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.
ForeSENTIA Prostate Tumor Profile Panel
| Single Nucleotide Variants / Insertions and Deletions | Copy Number Alterations | Translocations |
|---|---|---|
| AKT1, BRAF, CTNBB1, ERBB2, GNA11, GNAQ, KIT, KRAS, MAP2K1, NF1, NRAS, PIK3CA, POLE, PTEN, TP53 | ERBB2, KIT, KRAS, MYC, TP53 | ALK, BRAF, NTRK1, NTRK2, NTRK3, RET, ROS1 |
PROSTATE TUMOR PROFILE PANEL
Description
The ForeSENTIA prostate tumor profile panel tests for numerous genetic alterations that are frequently found in prostate tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.
Who is this test for?
Any patient diagnosed with prostate cancer can have tumor profile testing with the ForeSENTIA prostate panel to help identify the specific genetic alterations that are associated with their tumor.
Number Of Genes Tested
30
Sample: Unstained sections from tumor biopsy sample
Turnaround time: 2-3 Weeks
Genes Tested
The table below shows the genes tested by the ForeSENTIA prostate tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.
ForeSENTIA Prostate Tumor Profile Panel
| Single Nucleotide Variants / Insertions and Deletions | Copy Number Alterations | Translocations |
|---|---|---|
| AKT1, APC, AR, ATM, BRAF, BRCA1, BRCA2, CTNNB1, CHEK2, FOXA1, NRAS, PALB2, PIK3CA, PIK3CB, POLE, PTEN, RAD51D, SPOP, TP53 | AR, ERBB2, FGFR1, FGFR2, FGFR3, MYC, MYCN, PIK3CA, PTEN, RB1, TP53 | NTRK1, NTRK2, NTRK3, TMPRSS2 |
GLIOMA TUMOR PROFILE PANEL
Description
The ForeSENTIA glioma tumor profile panel tests for numerous genetic alterations that are frequently found in gliomas. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.
Who is this test for?
Any patient diagnosed with glioma cancer can have tumor profile testing with the ForeSENTIA glioma panel to help identify the specific genetic alterations that are associated with their tumor.
Number Of Genes Tested
22
Sample: Unstained sections from tumor biopsy sample
Turnaround time: 2-3 Weeks
Genes Tested
The table below shows the genes tested by the ForeSENTIA glioma tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.
ForeSENTIA Glioma Tumor Profile Panel
| Single Nucleotide Variants / Insertions and Deletions | Copy Number Alterations | Translocations |
|---|---|---|
| ATRX, BRAF, CIC, CTNNB1, EGFR, FUBP1, H3F3A, IDH1, IDH2, NF1, POLE, TERT, TP53 | 1p/19q codeletion, CDKN2A, EGFR, MET, MYC, MYCN, PTEN | BRAF, FGFR3, NTRK1, NTRK2, NTRK3 |
PAN-CANCER TUMOR PROFILE PANEL
Description
The ForeSENTIA pan-cancer tumor profile panel tests for numerous genetic alterations that are frequently found in several cancers. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.
Who is this test for?
Any patient diagnosed with cancer can have tumor profile testing with the ForeSENTIA pan-cancer panel to help identify the specific genetic alterations that are associated with their tumor.
Number Of Genes Tested
77
Sample: Unstained sections from tumor biopsy sample
Turnaround time: 2-3 Weeks
Genes Tested
The table below shows the genes tested by the ForeSENTIA pan-cancer tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.
ForeSENTIA Pan-Cancer Tumor Profile Panel
| Single Nucleotide Variants / Insertions and Deletions | Copy Number Alterations | Translocations |
|---|---|---|
| AKT1, ALK, APC, AR, ARAF, ATM, ATRX, BARD1, BRAF, BRCA1,BRCA2, BRIP1, CHEK2, CIC, CTNNB1,DDR2, DICER1, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FBXW7, FOXA1, FOXL2, FUBP1, GATA3,GNA11, GNAQ, GNAS, H3F3A, IDH1, IDH2, JAK2, KEAP1, KIT, KRAS, MAP2K1, MAP3K1, MET, MLH1, MRE11A, MSH2, MSH6, MTOR, NBN, NF1, NRAS, NTRK1, PALB2, PDGFRA, PIK3CA, PIK3CB, PMS2, POLE, PTEN, RAD51C, RAD51D, RAF1, RET, RUNX1, SMAD4, SPOP, STK11, TERT, TP53 | 1p/19q codeletion, AR, CDKN2A, EGFR, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, KIT, KRAS, MET, MYC, MYCN, PIK3CA, PTEN, RB1, TP53 | ALK, BRAF, FGFR3,NTRK1, NTRK2, NTRK3, RET, ROS1, TMPRSS2 |
THERAPY-ASSOCIATED TUMOR PROFILE PANELS
ForeSENTIA therapy-associated tumor profile panels focus on genes that are frequently involved in several cancer types.
EGFR KRAS+NRAS PIK3CA+AKT1 BRAF IDH1 + IDH2
Approved targeted therapies or ongoing clinical trials are available to treat specific cancer types caused by alterations in these genes.
HOW DO CANCER MUTATIONS DEVELOP?
Mutations (alterations) in our genes can happen in two ways: either we were born with them by inheriting them from our parents (hereditary), or we acquired them during our lives (somatic).
Somatic mutations can develop due to many risk factors such as smoking, high alcohol consumption, viruses such as HPV (human papillomavirus), exposure to mutagenic chemicals, and environmental pollutants. These alterations cannot be passed to our children. It could take years or decades for them to develop into cancer, depending on the mutations and the site they occur in.
KNOW YOUR GENES, KNOW YOUR CHOICES
When it comes to cancer, don’t rely on general statistical data and standardized treatment.
ForeSENTIA can potentially identify the genetic alterations (changes) that led to your tumor, providing useful information to your doctor in guiding your treatment
HOW DOES ForeSENTIA HELP ME?
ForeSENTIA identifies the characteristics that make your tumor unique. By finding the specific alterations involved in the tumor, your treatment could become precise and targeted – raising your chances of benefiting from your therapy.
With ForeSENTIA, your doctor will have reliable and detailed information of your tumor, allowing them to choose the most suitable treatment options, drug therapies and possibly even clinical trials for you, improving your clinical care.
WHY CHOOSE ForeSENTIA?
- Eligibility for targeted therapies
- Higher chances of successful treatment
- Improved prognostic insight
- Better clinical management
- Short turn-around time
- Proven technology
HOW IS ForeSENTIA PERFORMED?
ForeSENTIA uses a sample from the tumor biopsy that has already been performed.
TECHNOLOGY YOU TRUST
TARGETED TECHNOLOGY
By focusing only on the genetic alterations tested, ForeSENTIA is accurate and precise.
HIGH READ DEPTH
ForeSENTIA analyzes the locations of the genetic alterations hundreds of times, making the test more sensitive and reliable.
HOW IS ForeSENTIA ADMINISTERED ?
-
TALK TO YOUR DOCTOR ABOUT THE IDEAL PANEL FOR YOU
A SAMPLE FROM YOUR TUMOR
BIOPSY WILL BE SENT TO US
THE SAMPLE WILL BE ANALYZED
IN OUR LABORATORY
RESULTS WILL BE SENT TO YOUR DOCTOR IN 2-3 WEEKS
Depending on the panel, guidance on finding information on therapy choices and clinical trials will be provided.
FAQ
-
What is genetic testing?
Genetic testing identifies changes in the DNA. These changes might determine the health of an individual.
-
What are somatic mutations?
Somatic mutations, or alterations, are genetic changes in the DNA that happen after a person is born. These are acquired during a person’s lifetime due to risk factors like smoking, high alcohol consumption and environmental pollutants, and are not inherited. People with cancer have cancer-related somatic alterations in the tumor.
-
What is a tumor profile testing and why is it useful?
The same cancer type can be caused by different genetic alterations. These differences in the genetic profile of tumors account for the variability of symptoms, progress of disease and response to treatment. Tumor profile testing identifies the specific genetic alteration responsible for cancer development in each patient. The information gained by tumor profile testing allows for a more accurate and reliable prognosis, and helps the healthcare provider choose the most appropriate treatment for their patients depending on the tumor’s unique genetic characteristics.
-
Who should have tumor profile testing?
Any patient diagnosed with cancer can have tumor profile testing to help identify the specific genetic alterations that are associated with it. This information is critical for healthcare providers as it empowers them to provide a more precise clinical management and treatment that is tailored to the patient’s tumor profile and as such has better chances of being beneficial.
-
How can the ForeSENTIA tumor profile panels help?
The ForeSENTIA tumor profile panels give you the option to analyze a comprehensive list of genetic alterations found in tumor, allowing for the best chance to identify the genetic alterations that caused the cancer. This information will allow the healthcare provider to choose a treatment plan that is expertly fitted to the characteristics of the tumor, identify relevant clinical trials and approved therapies, thus providing the patient with improved prognostic insight and medical management.
Other Products
NIPD Genetics - Privacy Policy
General Statement
This Privacy Policy applies only to www.nipd.com and its subdomains (hereafter collectively referred to as “Sites") that link to this policy. NIPD Genetics Sites are owned by NIPD Genetics Public Company Ltd and are operated by NIPD Genetics Public Company Ltd and on occasion by a third-party that is responsible for the technical maintenance of the Sites.
If, you do not agree with this Privacy Policy, please do not access or use any of NIPD Genetics Sites.
NIPD Genetics values your interest in NIPD Genetics, its products and its services. NIPD Genetics takes the protection of your data seriously.
Personal data for purposes of this Privacy Policy, is any information by which you can be individually identified, including, but not limited to, your name, profession, address, e-mail address, and telephone number.
You may contact NIPD Genetics Public Company Ltd at
NIPD Genetics Public Company Ltd
Neas Engomis 31
Engomi, Nicosia
2409, Cyprus
NIPD Genetics Data Protection Officer can be reached at dpo@nipd.com
This Privacy Policy applies only to the Sites as defined above and which are operated by NIPD Genetics. The NIPD Genetics Privacy Policy seeks to inform the users of its Sites of the following:
- Type of personal information NIPD Genetics may collect through its Sites
- The ways by which NIPD Genetics collects, uses or shares such information
- Steps NIPD Genetics takes to protect its sites’ users personal information
- Your rights pertaining to your personal information, as explained in this Privacy Policy
NIPD Genetics will not use or share your information with anyone, except as described in this Privacy Policy. This Privacy Policy does not apply to any information we might collect by other digital and offline means and or from other digital and offline sources. The use of information collected through our Sites shall be limited to the purposes under this Privacy Policy and our Terms of Use to customers.
This page informs you of our policies regarding the collection, use, and disclosure of personal data when you use our Sites and the choices you have associated with that data.
We use your data to provide and improve the Sites. By using the Sites, you agree to the collection and use of information in accordance with this policy. Unless otherwise defined in this Privacy Policy, terms used in this Privacy Policy have the same meanings as in our Terms and Conditions, accessible from www.nipd.com
Type of personal information NIPD Genetics may collect through its Sites
Information Collection And Use
We collect several different types of information for various purposes to provide and improve our Sites and services to you.
Personal Data
While using NIPD Genetics Sites, you may be asked to provide NIPD Genetics certain personally identifiable information that can be used to contact or identify you ("Personal Information"). Personal Information that might be used to identify you includes, but is not limited to:
- Email address
- First name and last name
- Profession
- Phone number
- Address, State, Province, ZIP/Postal code, City
- IP address
If you send us a query via our Contact us form, your email address, the content and any follow up emails are retained indefinitely.
Cookies and Usage Data
Usage Data
We may also collect information how the Sites are accessed and used ("Usage Data"). This Usage Data may include information such as your computer's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Sites that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.
Tracking & Cookies Data
We use cookies and similar tracking technologies to track the activity on our Sites and hold certain information.
Cookies are files with small amount of data which may include an anonymous unique identifier. Cookies are sent to your browser from a website and stored on your device. Tracking technologies also used are beacons, tags, and scripts to collect and track information and to improve and analyze our Sites.
You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Sites.
Examples of Cookies we use:
Session Cookies. We use Session Cookies to operate our Sites.
Preference Cookies. We use Preference Cookies to remember your preferences and various settings.
Security Cookies. We use Security Cookies for security purposes.
Visitor behavior cookies. To understand how visitors use and navigate the Sites
Keyword cookies. To understand how visitors discover the Sites.
Use of Data
www.nipd.com uses the collected data for various purposes:
- To provide and maintain the Sites
- To notify you about changes to our Sites
- To allow you to participate in interactive features of our Sites when you choose to do so
- To provide customer care and support
- To provide analysis or valuable information so that we can improve the Sites
- To monitor the usage of the Sites
- To detect, prevent and address technical issues
Transfer of Data
Your information, including personal data, may be transferred to — and maintained on — computers located outside of your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.
If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.
Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.
www.nipd.com will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal data will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.
Disclosure of Data
NIPD Genetics complies with the protection of personal data regulation and will not sale or trade your personal data.
NIPD Genetics may disclose your personal data in the good faith belief that such action is necessary to:
- To comply with a legal obligation
- To protect and defend the rights or property of www.nipd.com
- To prevent or investigate possible wrongdoing in connection with the Sites
- To protect the personal safety of users of the Sites or the public
- To protect against legal liability
Security of Data
The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.
Service Providers
We may employ third party companies and individuals to facilitate, maintain or operate our Sites ("Service Providers"), to provide the SItes on our behalf, to perform service-related services or to assist us in analyzing how our Sites is used.
These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.
Analytics
We may use third-party Service Providers to monitor and analyze the use of our Sites.
Google Analytics
Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.
You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.
For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page
Access to your personal data, correction, deletion, and Opting Out
You have the right to review, update or delete any of your personal data by sending a request at NIPD Genetics Personal Data Officer pdo@nipd.com
Links to Other Sites
Our Sites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.
We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.
Children's Privacy
Our Service does not address anyone under the age of 18 ("Children").
We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.
Changes to This Privacy Policy
We may update our Privacy Policy from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.
We will let you know via email and/or a prominent notice on our Service, prior to the change becoming effective and update the "effective date" at the top of this Privacy Policy.
You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.